PAPER Dal Pra I, Chiarini A, Pacchiana R, Chakravarthy B, Whitfield JF, Armato U

Emerging concepts of how β-amyloid proteins and pro-inflammatory cytokines might collaborate to produce an 'Alzheimer brain' (Review).

Mol Med Report. 2008 Mar-Apr;1(2):173-8. PubMed: 21479393

PAPER Reifert J, Hartung-Cranston D, Feinstein SC

Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation.

J Biol Chem. 2011 Jun 10;286(23):20797-811. PubMed: 21482827

PAPER Hyman BT

Amyloid-dependent and amyloid-independent stages of Alzheimer disease.

Arch Neurol. 2011 Aug;68(8):1062-4. PubMed: 21482918

PAPER Schneider LS, Dagerman KS, Higgins JP, McShane R

Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

Arch Neurol. 2011 Aug;68(8):991-8. PubMed: 21482915

PAPER Sakurai T

Targets of the peroxisome proliferator-activated receptor γ agonist trials for the prevention of Alzheimer disease.

Arch Neurol. 2011 Apr;68(4):542; author reply 542-3. PubMed: 21482939

PAPER Shaw CA, Li Y, Wiszniewska J, Chasse S, Zaidi SN, Jin W, Dawson B, Wilhelmsen K, Lupski JR, Belmont JW, Doody RS, Szigeti K

Olfactory copy number association with age at onset of Alzheimer disease.

Neurology. 2011 Apr 12;76(15):1302-9. PubMed: 21482944

PAPER Sokol DK, Maloney B, Long JM, Ray B, Lahiri DK

Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links.

Neurology. 2011 Apr 12;76(15):1344-52. PubMed: 21482951

PAPER Corsi MM, Licastro F, Porcellini E, Dogliotti G, Galliera E, Lamont JL, Innocenzi PJ, Fitzgerald SP

Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration.

Biogerontology. 2011 Oct;12(5):451-4. PubMed: 21484243

Jim Burgess

Halifax, Canada

No Effect Seen in Huntington’s Disease Trial of Dimebon

RESEARCH NEWS 2011-04-13 Research News Dimebon, aka latrepirdine, failed to show efficacy in a Phase 3 clinical trial of people with Huntington’s disease, according to data released 11 April by the drug’s sponsors, Medivation Inc. and Pfizer. Over the course of six months, patien

Henrik Zetterberg on Plasma clusterin and the risk of Alzheimer disease.

COMMENT Using Rules-Based Medicine techniques and samples from a large population-based cohort, the authors show that clusterin levels in plasma are slightly elevated in Alzheimer's disease and also in other dementia forms as compared to non-demented individ

David Holtzman on Plasma clusterin and the risk of Alzheimer disease.

COMMENT I have been interested in clusterin for some time, as it is somewhat similar to ApoE in several ways. Clusterin is produced at high levels in the brain by astrocytes (like ApoE), It occurs in HDL-like particles in the brain (like ApoE), and it strongly in

Mary Sano

Mount Sinai School of Medicine
New York, United States

Wataru Kudo

United States

Robert Nelson

LUNDBECK RESEARCH
Paramus, United States